Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at fordelene ved Enviage opvejer risiciene ved behandling af essentiel hypertension.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Enviage are greater than its risks for the treatment of essential hypertension.